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Suppression of hepatitis B virus (HBV) replication, a causative agent for chronic hepatitis, is an effective approach to controlling disease
progression. Host factors have a significant effect on viral replication efficiency and need to be better characterized. We have reported association
between clinical virus load and deletions in HBV viral promoter. We showed here that HBV genome with such deletions led to decreased replication
compared with wild type virus. Consistently, the promoter with deletion showed lower activity. A cellular transcription regulator recognizing the
promoter with deletion was revealed in gel shift assay and subsequently identified as SMARCE 1 through DNA–protein array assay. The ability of
SMARCE 1 inmodulating the replication efficiency of HBVwas further demonstrated. Taken together, our studies show a direct dependence of HBV
on a host factor to modulate its replication efficiency, and provided a new platform for molecular characterization of mechanisms of disease outcome
as a result of binding of new transcription factors to rearranged promoter sequences.
© 2007 Elsevier B.V. All rights reserved.Keywords: HBV; Core promoter and deletion; Replication; DNA–protein interactions; SMARCE11. Introduction
Hepatitis B virus (HBV) infection is a serious public health
problem in many parts of world that results in complications
such as cirrhosis and hepatocellular carcinoma [1]. Globally,
despite effective vaccination against HBVand available antiviral
treatments [2], there remain an estimated 350 million hepatitis B
carriers with a lifetime risk for developing cirrhosis and hepato-
cellular carcinoma. Current antiviral therapies for HBV carriers
include treatment such as alpha-interferon or lamivudine, but the
long-term resolution of disease is disappointing due to low
seroconversion rates and the development of drug-resistant viral
mutants [3].
HBV belongs to a family of viruses known as hepadnaviridae
and encodes only four genes in a highly compact viral genome:
the surface gene (S), the core gene (C), the X gene (X), and the
polymerase gene (P). Viral replication has been shown to occur
via an RNA intermediate in the cytoplasm, but, unlike retro-⁎ Corresponding author. Tel.: +65 63162870; fax: +65 62259865.
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doi:10.1016/j.bbadis.2007.06.005viruses, integration of HBV DNA into the host genome is not
required. Despite a wealth of information on the virus itself and
the possible role that host factors may play in the viral infectious
life cycle [4], the direct relationship between chronic infection
and host–pathogen interactions is poorly understood.
The core promoter (CP) of HBV plays a central role in HBV
replication and morphogenesis. The core promoter controls the
transcription of two core gene products: core and precore RNA.
The core RNA is essential for viral replication, because it
encodes the major capsid protein and the viral polymerase.
Additionally, it also serves as the pregenomic RNA [5]. The
nonessential precore RNA encodes the precore protein, which is
processed in the endoplasmic reticulum to produce the secreted
HBeAg [6]. Previous studies have shown that deletion in the
core promoter can lead to suppression of viral replication and
HBV DNA [7,8]. Conversely, our previous investigation in
clinical serum samples has revealed that deletions in the viral
core promoter may result in an increase in viral replication as
indicated by the high level of HBV DNA [9]. In this case, high
serumHBVDNA level (∼228.16 pg/ml) as well as HBsAg level
(∼140 μg/ml) have been found in three patients in whom the
Fig. 1. Quantification of HBV DNA by Real-Time PCR. Two days after
transient transfection with HBV wild type or deleted constructs, HBV DNAwas
measured in culture medium. Mean values and standard deviations from three
independent experiments were shown. Values were normalized to HBV copy
number of the wild type construct (100%).
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(nucleotide 1758–1777, 1749–1768) of the viral core promoter.
It is likely that cellular transcription factors recognize the
altered viral promoter and modulate level of viral replication, as
evidenced in our recent investigation on the role of hetero-
geneous ribonucleoprotein K (hnRNPK) in HBV promoter with
single nucleotide mutation [10]. Analysis of virus–host interac-
tion at gene expression level should not only provide new
insights on the underlying mechanism of differential regulation
of viral replication, but more importantly identify new targets for
antiviral strategies.
In this study, a host protein—SMARCE 1 has been isolated
by direct binding to a viral DNA fragment corresponding to
HBV promoter region with deletion. The cotransfection
experiment and gel shift assay further confirmed the binding
affinity of SMARCE 1 to the DNA fragment. SMARCE 1 was
found to bind and modulate HBV replication. Taken together,
our studies show a direct dependence of HBVon a host factor to
modulate its replication efficiency, and provided a new platform
for molecular characterization of mechanisms of disease
outcome as a result of binding of new transcription factors to
rearranged promoter sequence.
2. Result
2.1. Deletions in HBV core promoter lead to decreased
extracellular HBV virion
Based on clinical samples, we have previously reported a
possible role of deletions within HBV core promoter in viral
replication [9]. To investigate the molecular mechanism of HBV
replication in this context, we have recently established a cell-
based HBV replication in which a replicative viral genome was
reconstructed with the same reported deletions in the core
promoter [11]. The amount of secreted HBsAg in cells trans-
fected with deletion mutants was significantly lower than those
transfected with the wild type genome [11]. In order to further
validate the influence of core promoter deletions on the HBV
replication capacity, the extracellular HBV DNA level was
measured. Newly synthesized HBV virions released into
supernatant were collected 2 days after transfection and HBV
DNA level measured using a quantitative real-time PCR
approach. The result shows deleted mutants displayed decreased
levels of released HBV virions in the supernatant (Fig. 1). Our
results were consistent with earlier report on the correlation
between the amount of HBsAg and that of HBV DNA level
which is indicative of HBV replication [10]. This in turn
suggested that deletions in core promoter led to a decreased viral
replication, in line with other reported investigations [7,8].
2.2. Deletions in HBV core promoter lead to decreased
intracellular HBV replication
While the extracellular amounts of HBsAg and HBV DNA
are indicative of HBV replication, a more direct measurement
would be the level of intracellular viral RNA [4], real time PCR
was used to measure the level of intracellular HBV core mRNA.HepG2 cells were transiently transfected with different
constructs including wild type HBV, HBV genome with deletion
type 1 (DEL1), and HBV genome with deletion type 2 (DEL2),
and mRNA was extracted from each type of HepG2 cells and
used as template for reverse transcriptase (RT)-PCR using
primer covering the coding region of HBV core. Then, the RT-
PCR core gene product was used as template to perform the
Real-Time PCR experiment. Conversely, the cellular house-
keeping gene GAPDH was included as an internal control.
Quantification of the PCR products in the calculated linear area
of amplification showed significantly decreased HBV core
mRNA level in the HepG2 cells transfected with HBV genome
containing deletions in their core promoter (Fig. 2). Compared
with the wild type, the mRNA level in the cells transfected with
either DEL1 or DEL2 was much lower. As the coding region of
HBV core was contained on the pregenomic RNA, our results
indicated that the amount of pregenomic RNA was reduced in
deleted mutants and thus HBV replication level was lower in
these mutants.
2.3. Deletions in HBV core promoter lead to decreased
promoter activity
As the above-mentioned deletions were in the HBVenhancer
element, the effect of these deletions on transcriptional effi-
ciency was analysed. A 131-base pair Enh II fragment covering
wild type region, the same region without nt 1749–1768 (DEL1)
and the same region without nt 1758–1777 (DEL2) were
separately cloned upstream of a SV40 promoter–luciferase
reporter gene vector. HepG2 cells were transiently transfected
with these constructs and the respective luciferase activity was
measured. The results shown in Fig. 3 indicated that DEL1 and
DEL2 displayed levels of luciferase that were significantly lower
compared with that of the wild type enhancer promoter. As a
positive control, the vector containing both the SV40 promoter
and enhancer sequences resulting in optimal luciferase expres-
sion was used (positive column 1, Fig. 3).
Fig. 2. Quantification of HBV Core gene Relative to GAPDH Expression.
Quantification of intracellular HBV Core gene expression in cells transfected
with replicative HBV genome with deletions in core promoter, in relation to that
of cells transfected with wild type HBV genome. Means and standard deviations
were based on more than three independent experiments.
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promoter–luciferase gene but without any enhancer element
(negative column, Fig. 3) was used as the negative control.
To determine if these results were specific to HepG2 cell
line, the above-mentioned transfections were carried out in
two cell lines: Chang liver cells and 293T cells. The results
shown in Fig. 3 indicated that the promoter activity of either
DEL1 or DEL2 was lower than that of the wild type HBV
core promoter which was consistent with the results in
HepG2. Our results therefore suggested that deletions
spanning nt 1749–1768 and/or nt 1758–1777 had a signi-
ficant effect on the transcriptional efficiency of Enh II. InFig. 3. Promoter activity assay in three cell lines. (a) HepG2, (b) Chang liver cell
line, and (c) 293T. Each type of cells was transfected with the respective Enh II
constructs (wild type, DEL1 or DEL2). For each cell type, the first column
represented the ratio of the luciferase activity of internal positive control
(promoter and enhancer). The second column (labeled as ‘negative’) represented
the ratio of activity of the negative control (promoter but no enhancer). The other
columns of each cell line represented the ratio of activity between vectors with
the promoter and the Enh II (wild type, DEL1 or DEL2) to that of pBIND.
Results of the luciferase assay were normalized to the level of the internal
positive control set at 100%. (For each cell line, the difference between wild type
and DEL1 was significant as indicated by a pb0.05. The difference between
wild type and DEL2 was also significant by a pb0.05).addition, our assay on the promoter activity provided further
support for the effect of deletions on the decreased HBV
replication.
2.4. Cellular protein SMARCE1 binds to HBV core promoter
with deletion in vitro
To further analyse the biological significance of DEL1 and/or
DEL2 with deletions in Enh II region of HBV core promoter, the
presence of direct physical HBV DNA–host interaction at the
deleted region was investigated. DEL1 was chosen in this study
by its more drastic decreased promoter activity compared to
DEL2.
Non-radioactive DEL1 oligonucleotide probe was designed
to contain the region surrounding nt 1749–1768, whereas the
control probes were designed based on the wild type sequence
which include the deleted region. Electrophoretic mobility
shift assay was performed using HepG2 nuclear extracts in the
presence of either the DEL1 or the wild type DNA probes.
Using nuclear extracts from HepG2 cells, four DNA–protein
complexes were detected and referred to as complexes I, II, III
and IV respectively (Fig. 4). The complex I may be a result of
nonspecific binding as it appeared for both wild type and
DEL1 probes. The intensity of signals of complex IV was
decreased by an unlabeled specific competitor. Significantly,Fig. 4. Analysis of Cellular Protein Binding to Probe Covering Deletion nt
1749–1768. Electrophoretic mobility shift assays were performed using
HepG2 nuclear extracts with two different biotinylated probes: the wild type
and DEL1. This DNA fragment was end labeled with biotin, incubated with
5 μg of HepG2 nuclear extract, and electrophosed on a 6% nondenaturing
polyacrylamide gel. Lane 1, labeled wild type probe alone without nuclear
extract. Lane 2, labeled wild type probe and HepG2 nuclear extract with 200
fold of unlabeled specific competitor. Lane 3, labeled wild type probe with
HepG2 nuclear extract. Lane 4, labeled DEL1 probe alone without nuclear
extracts. Lane 5, labeled DEL1 probe and HepG2 nuclear extract with 200
fold of unlabeled specific competitor. Lane 6, labeled DEL1 probe with
HepG2 nuclear extract probe. I, II, III, and IV marked the locations of DNA–
protein complexes I, II, III, and IV respectively. FP indicated free labeled
DEL1 probe.
Table 1
Identify of transcription factors immobilized of TF array
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specific competitor. This result indicated that a distinct DNA
binding protein was associated with the DEL1 probe in
complex III (lane 6, Fig. 4). These data suggested that host
DNA-binding proteins interacted directly with the DEL1 probe
and may be involved in our observed decrease in the correlated
viral replication.
To identify transcriptional factors which bind to this specific
DEL1 probe, a protein–DNA array (Table 1) was used. The
commercially available array contained immobilized transcrip-
tion factors, and incubation with DNA probes of interest would
provide direct indication of protein–DNA interaction. Either
wild type or DEL1 biotinylated probes were used in the
analysis with the protein–DNA array. To assess the significance
of any positive signal, a duplicate blot was then used in
competition analysis using an excess non-biotinylated DNA
probes. The absence or drastically reduced intensity of the
positive signal in the duplicated blot would suggest that theFig. 5. DNA–protein array assay. The response elements on the array are spotted in du
were spotted. The transcription factor array was incubated with the biotinylated DEL
probe panel B. Specific DNA–protein interactions (boxed) were competed out with
type probe. The array was incubated with the biotinylated wild type probe panel C a
Specific Protein/DNA interactions (boxed) were competed out with non-biotinylatedrespective the transcription factor interacted with DNA probe
being analysed. Results shown in Fig. 5A and B indicated that
five transcription factors recognized DEL1 but not the wild
type probe.
The samples were also compared with the blot of protein–
DNA incubated with the wild type DNA probe. Results shown in
Fig. 5C and D indicated a different pattern compared to those
obtained from DEL1 (Fig. 5A and B). Proteins that were
recognized by DEL1 probe included PTTG1, PTTG2, PXR2,
SIX2, SMARCE1 and TFE3 (Fig. 5A), while binding to wild
type probe was seen with REVERB and SP3 (Fig. 5C).
Significantly, all these detected protein–DNA interactions
were reduced in a competitive manner in the presence of the
respective non-biotinylated probe. This was shown in Fig. 5B
for DEL1 DNA probe and in Fig. 5D for wild type DNA probe
respectively.
Among the positive DNA–protein interactions detected in
DEL1 DNA probe, the interaction between DEL1 probe andplicate. The right and bottom sides of the array indicate where biotinylated DNA
1 probe panel A and both biotinylated and an excess of non-biotinylated DEL1
non-biotinylated probe. Panels C and D: results of the array incubated with wild
nd both biotinylated and an excess of non-biotinylated wild type probe panel D.
probe.
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dependent regulator of chromatin subfamily E member 1-related
protein) was completely removed in the presence of non-
biotinylated DEL1 probe (Fig. 5B). SMARCE 1 was therefore
selected for further in vitro analysis for its role in HBV
replication mediated by viral promoter containing DEL1
deletion.
To investigate whether the full-length SMARCE1 protein
interacts in vitro with DEL1 but not the wild type, the coding
region of SMARCE1 was amplified, cloned in mammalian
expression vector pXJ40 and the protein produced in 293Tcells.
The 293T cell line was selected as the decrease in deletion
promoter activity (Fig. 3c) was less drastic compared with that in
HepG2 or Chang cell lines (Fig. 3a and b). This would be more
useful when the effect of SMARCE1 on DEL1 was subse-
quently analysed, as the relatively higher promoter activity for
DEL1 in 293Tcells (45.92%) compared with that in HepG2 cells
(6.95%) would allow more accurate measurement of the
changes either by activation or by repression. The production
of full-length SMARCE1 protein in 293T cells was further
indicated by Western blot analysis using HA tag monoclonal
antibody (Fig. 6). The presence of 46 kDa protein, correspond-
ing to the expected size of SMARCE1 protein, in 293T cells
transfected with pXJ40-SMARCE1 construct (lane 1, Fig. 6) but
not 293Tcells transfected with the empty pXJ40 plasmid (lane 2,
Fig. 6) suggested that full-length SMARCE1 protein was
produced in these cells.
Electrophoretic mobility shift assay was then carried out with
DEL1 and wild type DNA probes separately, using nuclear
protein extracted from 293T cells producing full-length
SMARCE1. Nuclear proteins extracted from 293T cells
transfected with cloning vector were used as negative control.
After electrophoresis and membrane transfer, both DNA–
protein complexes and free probes were identified with
streptavidin–horseradish peroxidase and substrate. As shown
in Fig. 7, DNA–protein complex II was seen when DEL1 probe
was incubated with nuclear proteins from SMARCE1 trans-
fected cells (lane 2, Fig. 7B), but not when wild type probe was
incubated with the same nuclear protein (lane 5, Fig. 7B).
Addition of excessive non-biotinylated DEL1 probe was able to
compete off the binding of biotinylated DEL1 probe to complex
II, as shown by its reduced intensity (lane 1, Fig. 7B), suggesting
that complex II was formed by DEL1–protein interaction. TheFig. 6. Analysis of SMARCE1 protein level. Western blot analysis was carried
out using HA tag monoclonal antibody. A 46-kDa protein corresponding to
SMARCE1 was detected in lane 1 (293T cells transfected with pXJ40-
SMARCE1). No protein was detected in lane 2 (293T cells transfected with
pXJ40 plasmid).involvement of SMARCE1 in complex II was supported by its
absence in the electrophoretic mobility shift assay using nuclear
proteins from 293T cells transfected with pXJ40 plasmid (lanes
1 and 2, Fig. 7A). Furthermore, the complex II was not detected
in other conditions where either DEL1 probe or SMARCE1
protein was not present: including the absence of nuclear
proteins (lanes 3 and 6, Fig. 7A; lanes 3 and 6, Fig. 7B),
incubation of nuclear protein with the wild type probe (lanes 4
and 5, Fig. 7A; lanes 4 and 5, Fig. 7B) and incubation with
nuclear proteins from cells transfected with the empty pXJ40
(Fig. 7A). Our results therefore suggested that DEL1 DNA
fragment interacted in vitro with SMARCE1 protein.
To further support that the complex III was indeed formed by
DEL1 probe and SMARCE1, the supershift assay was carried in
the presence of the anti-HA antibody which should recognize the
SMARCE1 expressed as a HA-tag protein (see Fig. 6). Results
suggested that partial supershift was detected for complex III in
the presence of anti-HA antibody (arrowhead, lane 4, panel C,
Fig. 7). This partial supershift band was not detected in the
absence of the anti-HA antibody (lane 2, panel C, Fig. 7). As a
control, the unlabeled specific probe was able to compete off the
DNA–protein complexes (including complex III) detected in
lanes 2 and 4. Our results therefore indicated that complex III
was formed by DEL1 probe and SMARCE1.
2.5. SMARCE1 modulates replication of mutant HBV with
deletion in viral promoter
To investigate whether SMARCE1 bind to HBV core
promoter with DEL1 deletion, the above-mentioned transcrip-
tion reporter system for promoter activity assay was used. In this
case, HepG2 cells were co-transfected with either DEL1 reporter
construct/pXJ40-SMARCE1 or wild type reporter construct/
pXJ40-SMARCE 1 and effect of SMARCE1 analysed by
luciferase activity. Results shown in Fig. 8 suggested that
SMARCE1 exerted a stronger repression effect on DEL1
promoter, as the DEL1 promoter activity was repressed from
41.25% to 26.2%. As a control, the repression effect of
SMARCE1 was not significant towards the wild type promoter
with the wild type activity at 85.35% repressed slightly to
79.65% (Fig. 8). This was expected as our blot binding and in
vitro analyses indicated no interaction between SMARCE1 and
the wild type DNA probe. These results indicated that
SMARCE1 not only interacted with DEL1 DNA fragment, but
also influence the promoter activity.
To determine the functional significance of SMARCE1 on
HBV replication, the amount of HBsAg secreted into culture
medium was analysed as previously reported [11]. This was
based on the simplicity of HBsAg measurement, and more
importantly on the close correlation between the amount of
HBsAg and HBV replication as demonstrated in this study (Fig.
2). pXJ40-SMARCE1 plasmid was co-transfected into 293T
cells with either the wild type replicative HBV genome or the
replicative viral genome with DEL1 deletion in the core
promoter (Pan et al., 2005). It is interesting to note that both
the wild type or DEL1 replicative genomes had been cloned
upstream of the CMV promoter of pcDNA3.1 such that the
Fig. 7. Gel shifty assay on DNA binding specificity of SMARCE1 expressed in mammalian cells. Panel A, binding of probes (wild type or DEL1) to nuclear extracts
from 293T cells transfected with pXJ40 plasmid. 200 fold in excess of non-biotinylated DNA probes were added as competitors in gel shift assays. I, II, III, IVand V
mark the location of the complexes. Panel B, binding of probes (wild type or DEL1) to nuclear extracts from cells transfected with pXJ40-SMARCE1 vector and
producing SMARCE1 protein. Panel C, supershift assay in the presence of anti-HA antibody. Lane 1, only the labeled DEL1 probe was added. Lane 2, the labeled
DEL1 probe was incubated with nuclear extract from cells transfected with the SMARCE1 construct. Lane 3, 200 fold in excess of the unlabeled DEL1 probe was
added with the labeled DEL1 probe and the SMARCE1 expressing nuclear extract. Lane 4, the anti-HA antibody was added to the SMARCE1 expressing nuclear
extract before the addition of labeled DEL1 probe. Arrowhead indicated the partial shift of DEL1–SMARCE1 complex.
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rather than the CMV promoter.
Consistently with our in vitro analysis indicating a repression
effect by SMARCE1, the amount of HBsAg from cells
transfected with DEL1 replicative genome decreased in the
presence of SMARCE1 (26.37% with SMARCE1 as opposed to
36.8% without SMARCE1, Fig. 9). t test was used for thestatistic analysis. Avalue of pb0.05 indicates that the difference
is significant. We concluded that the replicative genome with
deletion in the core promoter had lower replication efficiency. In
addition, cells transfected with 5 μg of SMARCE1 had lower
amount of secreted HBsAg compared with those transfected
with 1 μg of the same plasmid, suggesting that SMARCE1 was
indeed involved in the repression of HBsAg secretion (data not
Fig. 8. Luciferase activity with or without SMARCE1. 293T cells transfected
with the respective Enh II constructs (wild type or DEL1) were assayed for the
effects of SMARCE1. For each cell type, the first column represented the ration
of the luciferase activity of internal positive control (promoter and enhancer)
from pBIND plasmid. The second column represented the ratio of activity of the
internal negative control (promoter only). The other columns of represent the
ratio of activity between Enh II (wt, del1, del2) vectors to that of positive
control. Cells cotransfected with pXJ40-SMARCE1 plasmid were in shaded
column. Results of the luciferase assay were normalized to the level of the
internal positive control (set at 100%).
Fig. 9. Semi-quantitative measurement of extracellular HBsAg. Two days after
transient cotransfection with HBV replicative genome and SMARCE1 over-
expression vector and empty vector, the culture medium was collected and
HBsAg was measured by IMX (Abbott Laboratories, USA). Mean HBsAg
values were obtained from three independent experiments.
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not significant towards the wild type replicative genomewith the
amount of HBsAg at 50.89% reduced slightly to 49.94% (Fig.
9). This was expected as our blot binding and in vitro analyses
indicated no interaction between SMARCE1 and the wild type
viral promoter. These results indicated that SMARCE1 not only
interacted with DEL1 promoter, but also influence replication of
DEL1 genome.
In summary, our results provide evidence on the interaction
between cellular protein SMARCE1 and HBV promoter with
DEL1 deletion, and more importantly demonstrate the function
correlation between DNA–protein recognition and HBV
replication.
3. Discussion
The interesting observation that chronic HBV carriers have
different serum viral loads prompted us to investigate host
proteins involved. To understand whether the natural deletions
at 1749–1768 and 1758–1777 had any functional impact,
reporter constructs were developed to test effects of such
deletions on the ability to drive reporter gene transcription. It
was evident that both deletions had lower activity than the
wild type constructs. Transcription factors bind specifically to
promoter sequence. Such binding will be affected if the
binding site is removed by deletion for example. On the other
hand, the rearranged sequence in the promoter from a deletion
may create binding sites for new transcription factors. For
HBV, it has been reported that even one base pair change in
promoter region (1752 G/A) has resulted in the binding of
hnRNP K, and leading to the suppression of HBV replication
[10]. In addition, some of the mutations in the core promoter
have resulted in binding sites for hepatocyte nuclear factor 1and HNF3 [12]. It is therefore not surprising that the 20-bp
deletion in the core promoter may lead to binding of new
transcription factors including SMARCE1 as demonstrated in
our investigation.
To investigate the underlying basis for this enhanced tran-
scriptional activity, a new approach based on directly probing for
physical DNA–protein interactions was developed. Using an
initial electrophoretic mobility shift assay followed by a DNA–
protein array assay, a deletion (1749–1768) oligonucleotide
fragment (DEL1) was found to bind to a host binding factor. The
binding factor was identified as SMARCE1, a known protein
that has been shown to be involved in a number of cellular
functions. The full name of SMARCE 1 is SWI/SNF-related
matrix-associated actin-dependent regulator of chromatin sub-
family E member 1-related (SMARCE 1-related protein) (HMG
domain protein HMG20B) (Structural DNA-binding protein
BRAF35) (BRCA2-associated factor 35) (Sox-like transcrip-
tional factor). Its subcellular localization is in both nuclear and
cytosol. Members of the Swi/Snf family of chromatin-remodel-
ing complexes play critical roles in transcriptional control. These
complexes can be divided into three classes on the basis of the
similarities of their ATPase subunits to the Swi2/Snf2, Isw1, and
Mi-2 proteins [13]. The human SWI/SNF complexes contain
either BRG1 or Brm as the catalytic ATPase subunit and appro-
ximately 10 BRG1-associated factors (BAFs). The BAF170 and/
or BAF155, BAF60, BAF57, BAF53, and BAF47 (hSNF5/Ini1)
subunits are present in all mammalian SWI/SNF complexes and
conserved from yeast to humans, except for BAF57 [14].
Ample experimental evidence has suggested that the SWI/
SNF complexes play important roles in fundamental cellular
processes such as transcription, replication, and the repair of
chromatin [13,15]. As a result, mammalian SWI/SNF complexes
have been implicated in diverse physiological and pathological
processes, including cell proliferation and differentiation, retro-
virus infection, and carcinogenesis [14]. It has been reported that
both recombinant BAF57 and the whole complex bind double
strand DNA [16].
In this study, the cotransfection experiment and gel shift assay
further confirmed the binding affinity of SMARCE1 to DEL1
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a full-length HBV genome containing the same DEL1 deletion
in its promoter. To this end, cells were co-transfected with the
full-length replicative HBV genome constructed [11] carrying
such a deletion (DEL1) and pXJ40-SMARCE1 plasmid.
Compared with similar transfection where the replicative
genome was used instead, the replication of wild type genome
as measured by the extracellular amount of HBsAg was higher
than DEL1 genome. Interestingly, no significant difference in
replication was seen in cells transfected with the wild type
genome with or without pXJ40-SMARCE1. Consistently with
the in vitro analyses including the promoter activity (Fig. 8) and
gel shift assay (Fig. 7), the presence of SMARCE1 protein led to
a decrease in the amount of HBsAg from cells transfected with
DEL1 genome.
It appears that SMARCE 1 could downregulate the tran-
scription. In several recent studies, chromatin immunoprecipita-
tion (ChIP) experiments demonstrated that Swi/Snf components
were physically present at repressed promoters. Targeted
repression by Swi/Snf appears to require its recruitment by
regulatory proteins. In one study, the potential tumor suppressor
prohibition, which represses E2F activation, was shown to recruit
Swi/Snf to particular E2F-dependent promoter where they inhibit
E2F-mediated transcription [17]. In another study, Swi/Snf was
shown to be recruited to neuronal genes by the CoREST
corepressor, which itself interacts with the DNA binding repressor
[18]. In this case the CoREST–Swi/Snf interaction is dependent
uponBAF57.Besides its role in chromatin remodeling, SMARCE1
(also known as BAF57) has recently been shown to bind directly to
the promoter of the cylindromatosis tumor suppressor gene, and
induces apoptosis by stimulating its expression [19].
Taking these known functions of SMARCE1 into the context
of its new findings shown in this study, it is possible that other
cellular protein factors, some of which may have been identified
using our DNA–protein blot binding approach (Fig. 5), could act
in concert to support the replication activity of HBV in the host.
The mechanistic aspect of SMARCE 1 on HBV replication
needs to be further explored which should provide insights into
defining virulence and fitness of a virus.
It is interesting to note that our in vitro analysis showing an
overall reduction in activity (either in HBsAg or promoter
activity) for HBV genome carrying naturally occurring dele-
tions, while the opposite situation with high level of HBV DNA
has been observed in clinical samples [9]. This paradox could be
explained by the more heterogeneous nature of clinical samples,
as these may contain not just the HBV variant with deletions in
the core promoter but also other mutant strains. Furthermore,
natural mutations occurring on other parts of HBV genome
could also influence the overall replication. Nevertheless, the in
vitro analysis reported in our study provides a valuable platform
to study the underlying mechanism of regulation in a homo-
geneous condition.
In addition to our earlier report [9], deletions within HBV
core promoter have been identified in other clinical samples
[20]. Similarly to our findings in this study, such deletions have
been found to reduce the amount of extracellular HBsAg [21].
However, no cellular proteins recognizing HBV core promoterwith deletions have been characterized to date. Therefore, the
identification and characterization of SMARCE1 reported in this
study not only provides new approach in analysing DNA–
protein interactions, but also provide a starting point for further
molecular understanding of regulation of HBV replication by
host proteins.
In summary, a host protein SMARCE1 immobilized on a
membrane was isolated by direct binding assay using a DNA
fragment corresponding to HBV core promoter with deletion.
Furthermore, SMARCE1 was found to bind to and repress the
replicative efficiency of HBV genome containing the same
deletion in viral promoter. Our approach has opened a new way
to study DNA–protein interaction and more significantly hold
promise in identifying a new class of targets for the intervention
of chronic hepatitis B infection.
4. Materials and methods
4.1. Construction of plasmids
Construction of the replicative HBV genome containing deletions in the viral
core promoter was carried out using pcDNA3.1+ mammalian expression vector
(InvitroGen, USA), as described previously (Pan et al., 2005). Plasmids pGL3-
Control (a Luciferase plasmid with SV40 enhancer and promoter) and pGL3-
Promoter (an enhancerless luciferase plasmid with SV40 promoter upstream of
luciferase gene) were from Promega (USA). Plasmid pGL3-Promo/wt was
constructed by amplifying the basic functional unit of Enh II by PCR using
primers LucF5′-GCACGCGTCAACGACCGACCTTGAGG-3′ LucR5′-GCA-
GATCTACCAATTTATGCCTACAGCCTC-3′ comprising HBV nucleotide
positions 1686–1801. The 131-base-pair PCR fragment wasMluI/BglII-digested
and ligated with MluI/BglII digested pGL3-Promoter. The other deletion
constructs were constructed using pcDNA3.1+/DEL1 and pcDNA3.1+/DEL2
as template to introduce the HBV Enh II deletions. The first deletion was at
nucleotide position 1749–1768, the second deletion was at nucleotide position
1758–1777. All constructs were confirmed by sequencing. SMARCE1
expression construct was carried out by cloning a 1.2-kb RT-PCR fragment
corresponding to its coding region (amplified from total RNA extracted from
HepG2 cells) into the pXJ40 plasmid (kindly provided by Dr. CGKoh), in-frame
with a HA tag.
4.2. Cell culture and transfection
Three cell lines (HepG2, Chang liver cells, and 293T) were used in this study.
Theyweremaintained at 37 °C in a humidified atmosphere of 5%CO2 in DMEM
supplemented with penicillin (100 IU/ml) and Streptomycin (100 μg/ml) and
10% fetal calf serum. Transfection of individual construct was carried out using
Effectene (Qiagen, Germany), and culture medium and/or cells were harvested
48 h after transfection.
4.3. Measurement of extracellular HBsAg
2 μg of each of the constructs with deletions in the viral core promoter, as well
as the wild type HBV genome in pcDNA3.1 vector were transfected separately
into cells (HepG2, Chang or 293T) using Effectene transfection reagent (Gibco
BRL, Life Technologies, USA). Each transfection was carried out in three
independent experiments. Two days after transfection, culture medium was
collected and 200 μl were used for the measurement of HBsAg (Auszyme kit,
Abbott Laboratories, USA).
4.4. Quantification of HBV DNA from supernatant and intracellular
mRNA by real-time PCR
QIAamp DNA Blood Mini Kit (Qiagen, Germany) was used to isolate
HBV particles from culture medium of transfected cells. Conversely, mRNA
1083H. Pan et al. / Biochimica et Biophysica Acta 1772 (2007) 1075–1084from transfected cells was isolated using Oligotex mRNA mini kit (Qiagen,
Germany). Relative HBV DNA level was measured by real-time PCR
(ICycler Instrument, Bio-Rad, USA) using primers specific to HBV core
gene. Experiments were done in triplicate.
4.5. Luciferase assay
For the luciferase assays, 1 μg of plasmid DNA together with 1 μg of
control/promoter luciferase plasmid–DNA pBind was used for each transfec-
tion mix, and, after incubation for 48 h at 37 °C, cells were harvested with Cell
Culture Lysis Reagent (CCLR; Promega). 20 μl of cell lysates was mixed with
100 μl of Luciferase Assay Reagent (Promega), and luciferase activity was
measured as relative light units determined with a Turner 20/20 luminometer
(Promega, USA). pBIND luciferase activity was used to normalize the
transfection efficiency. Relative luciferase activity was expressed as fold
increase over vector without the enhancer element. Experiments were
performed in triplicate. For analysis of SMARCE1, luciferase assay was also
applied as follows: 293T cells were first transfected with luciferase reporter
constructs and SMARCE1 expression vector. After removing the culture
medium and rinsing twice with PBS, 200 μl of cell lysis buffer was added to
the cells, which were then shaken at room temperature for 15–20 min. The
cells were dislodged by scraping or pipetting and then transferred to a 1.5-ml
microcentrifuge tube before being centrifuged at 14,000 rpm at room
temperature for 1 min to remove cellular debris. 10 μl of the cell extract
was mixed with 50 μl of substrate (Promega, USA), and luminescence
measured.
4.6. Preparation of nuclear protein extracts and gel-shift
Cultures were trypsinized, rinsed twice with ice-cold PBS, and incubated
on ice. Nuclear extraction from cells was conducted using the NE-PER
Extraction kit (PIERCE, USA) according to the manufacturer's instruction.
Nuclear extracts were then aliquoted and stored at −80 °C. Protein
concentration was quantitated with the Protein Assay kit (Bio-Rad
Laboratories, Hercules, USA) using Ig G as standard. Gel shift assay was
conducted using the Gel shift assay kit (PIERCE, USA) according to the
manufacturer's instruction. Binding reaction procedures were performed at
37 °C for containing 3 μg of HepG2 nuclear extracts, free DNA and DNA–
protein complexes were resolved on 6% non-denaturing polyacrylamide gels.
The sequences of the oligonucleotide probes were as follows:
WT forward: 5′-(biotin) gggaggagct gggggaggag attaggttaa aggtctttgt
attaggaggc tgta-3′.
WT reverse: 5′-taca gcctcctaat acaaagacct ttaacctaat ctcctccccc agctcctccc-3′.
DEL 1 forward: 5′-(biotin) gggaggagctgggggag tgtattaggaggctgta-3′.
DEL1 reverse: 5′-tacagcctcctaataca ctcccccagctcctccc-3′.
4.7. Protein–DNA array analysis
For DNA–protein interaction assay, the procedure was conducted using the
protein–DNA array kit (Panomics, USA) according to the manufacturer's
instruction. Briefly, annealed biotinylated probes were incubated with the
membranewith immobilized transcription factors for 30min at room temperature
and after wash, the membrane was incubated with the diluted streptavidin-HRP
for 30 min at room temperature.
4.8. Confirmation of DNA–protein interaction
For gel shift assays, the nuclear extracts from 293T cells which
overexpress pXJ40-SMARCE1 were incubated with individual biotin-labeled
probes in binding buffer for 20 min at room temperature. The negative
control consisted of free probe and without nuclear extracts. For the
competition control, an excess of unlabeled cold probes (wild type cold
probes and deletion 1 cold probes respectively) was added to the sample
containing nuclear extract and biotin-labeled probe. The samples were
separated on a 6% polyacrylamide gel in 0.5% Tris–borate–EDTA,
transferred onto a nylon membrane, and fixed on the membrane by UV
cross-linking. The biotin-labeled probe was detected with streptavidin–horseradish peroxidase (Pierce, USA). For supershift assay, in addition to the
procedures as described above, with the exception that 2 μg of anti-HA
(Santa Cruz) antibodies was incubated with the nuclear cell extract for 30 min
on ice before the addition of the biotin-end-labeled DEL1 probe. The samples
were then treated as described above.
4.9. Western blot analysis
The protein extracted from 293T cells transfected with pXJ40-SMARCE1
vector and from normal 293T cells was separated on a 7.5% SDS gel and
electroblotted onto nitrocellulose membranes. The membrane was then
incubated with a monoclonal antibody against HA (Santa Cruz, USA). After
incubation with a secondary antibody (PIERCE, USA), the membrane was
overlaid with luminol enhancer and substrate for 5 min. The image was acquired
using a fixer and developer (Kodak Corp., USA).
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